Anita Shaffer | Authors


Durable Complete Remissions Achieved in NHL Following CAR T

December 08, 2019

Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.

New Approaches Target Overcoming Resistance to TKIs in EGFR+ NSCLC

June 02, 2019

The treatment of EGFR-mutant non–small cell lung cancer has experienced significant improvements with the development of tyrosine kinase inhibitors, but resistance mechanisms that promote disease recurrence have tampered the runaway success of these revolutionary agents, said Katerina A. Politi, PhD, during the 2019 ASCO Annual Meeting. Early findings are presented for 2 novel agents aiming to potentially overcome resistance.